Good day, and welcome to the Green Thumb Industries' second quarter 2024 earnings conference call and webcast. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. On today's call, management will provide prepared remarks, and then we will open up the call for your questions. To ask questions, analysts may press star, then one on their touchtone phones. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Shannon Weaver. Please go ahead, ma'am. Thanks, Nick. Good afternoon, and welcome to Green Thumb's Second Quarter 2024 Earnings Call. I'm here today with founder and CEO, Ben Kovler, President Anthony Georgiadis, and Chief Financial Officer, Matt Faulkner. Today's discussion and responses to questions may include forward-looking statements, which are subject to various risks and uncertainties that could cause our actual results to differ materially from these statements. These risks and uncertainties are detailed in the earnings press release issued today, along with the reports filed with the United States Securities and Exchange Commission and Canadian Securities Administrators, including our most recent annual report filed on Form 10-K. This report, along with today's earnings release, can be found under the Investors section of our website. Green Thumb assumes no obligation to update or revise any forward-looking statements to reflect events or circumstances that may arise after the date of this call. Throughout the discussion, Green Thumb will refer to non-GAAP financial measures, including EBITDA and adjusted EBITDA. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in our earnings press release and SEC and CSA filings. Please note, all financial information is provided in US dollars, unless otherwise indicated. Thanks, everyone, and now here's Ben. Thank you, Shannon. Good afternoon, everyone, and thank you for joining our second quarter 2024 conference call. I'm pleased to report that our team delivered another strong quarter with revenue up 11% over the prior year to $280 million and over $90 million in EBITDA. Importantly, cash flow from operations was $20 million after paying almost $53 million in two tax installments this quarter. On June 28th, the IRS issued a statement that made it clear that cannabis companies were obligated to pay taxes under 280E while cannabis remains a Schedule I controlled substance. Thus, the regulatory attention is squarely on the DEA and leader Anne Milgram, and whether or not she chooses to reschedule cannabis to Schedule III, engage in an ALJ review process, or stay silent until the next administration. For the good of the country, we encourage Anne Milgram to do her job and reschedule cannabis immediately. No more waiting. During the second quarter, we also repurchased 1.6 million shares for approximately $20 million, bringing the aggregate spend under the share repurchase program to $73 million for approximately 6.6 million shares. Under the current program, we still have the option to repurchase almost $27 million in shares. We believe in the value-creating nature of share buybacks at attractive prices. We ended the quarter with $196 million in cash. That's plenty of dry powder to execute our capital allocation plan for 2024 and beyond. From an industry perspective, there is still price compression in most markets, as well as inflationary pressure, not to mention national anxiety around the upcoming elections. Despite this uncertainty, we are focused on the product, our brands, and the relationship with the consumer. Green Thumb will continue following our same playbook since day one: scaling our business through retail store expansion, building out our wholesale business, leveraging operational efficiencies, and carefully managing our balance sheet. Green Thumb has some of the top-rated brands in the business, RYTHM, Dogwalkers, Incredibles, and Beboe, and we're focusing a lot of energy this year on expanding brand awareness by creating meaningful experiences for consumers, authentic relationships, especially through the power of music. We recently announced that our Miracle in Mundelein two-day festival will be back this year with a highly anticipated lineup of musicians, including cannabis icon, Wiz Khalifa. The RYTHM Artist Series features strains chosen and smoked by artists such as multi-platinum R&B disruptor, Tinashe. Tinashe's Green T has created a lot of great buzz. Music is also at the core of Bud Ball, an annual concert we throw in-market, which we've opened up to Philly for the first time this year. We saw a record turnout at these events, and the Find Your RYTHM lifestyle was on full display. We are also excited to bring more of our brands to new markets, with Beboe launching in New York just last month. That's going well, and plans to expand to New Jersey very soon. We like the progress in our brands, but believe this is just the beginning of how these lifestyle brands will live in America. We want our brands to become integral to the American experience, and we are intensely watching consumer trends. We believe alcohol is melting, and for folks under 35 years old, alcohol is a lot less appealing than it was for their parents. This line of thinking led us to approach Boston Beer about a possible combination. Green Thumb has 50% more in EBITDA than Boston Beer, and we think consumer trends will force Boston Beer and others to diversify away from alcohol into products the future American consumer wants. I outlined the benefits of combining our two businesses, including a potential U.S. listing for Green Thumb, in my letter to Boston Beer's chairman and founder, and posted that on X. It often takes time for an incumbent industry to recognize and embrace change. In the meantime, Green Thumb will do what we have always done: keep our head down and execute, focus on building shareholder value through prudent capital allocation, all the while using the consumer as our North Star. Stopping for a moment and looking around to where we are, we feel good. Green Thumb is gaining market share in U.S. cannabis as our brands build momentum. Furthermore, we are well-positioned in the emerging cannabis markets like Ohio, where we will kick off adult-use sales at all five of our RISE Dispensaries tomorrow morning. Looking forward to seeing our incredible team in action on day one in the Buckeye State. We see a nice, long runway for growth and are confident in our team's abilities to strategically and profitably scale our business in Ohio. With that, I'll turn the call over to Anthony. Anthony? Thanks, Ben. As you just heard, despite continued consumer inflationary headwinds, our team achieved record-setting quarter results. Let's take a look at some of the highlights. First, we invested approximately $20 million in CapEx as we continue to expand our Florida retail footprint, as well as our Connecticut wholesale facility. Through June, we've opened three new stores and anticipate opening another seven to eight stores in the back half of the year. Year- to- date, we've invested approximately $35 million in CapEx, and expect to invest an additional $50 million-$60 million in CapEx throughout the remainder of the year. Second, we continue to drive strong CPG performance across our fleet and increased our CPG revenue by over 15% compared to Q2 of last year. As our retail business continues to absorb the impact of price erosion and greater competition, we plan to enhance our market position by increasing both the depth and breadth of our product lines and their placement on third-party shelves. For those that saw it, Beboe recently launched in New York, and we are incredibly excited to introduce her to the Big Apple. Third, we prepared for tomorrow's Ohio launch. We have the team hired, the store is ready, and our menus are stacked with something for everyone. Our recent adult-use conversions in New Jersey, New York, and Maryland have prepared us well for tomorrow's historic event. As we look ahead to the balance of the year, our team is focused on the following: First, optimizing our business. This means different things depending on market dynamics and our position within each market. However, when you zoom out, it comes down to focusing on the consumer, our team, and execution. Second, driving continued distribution of our CPG brand through our RISE retail stores as well as third-party stores. While we've made substantial progress on this front, we have more work to do to continue expanding the reach of our industry-leading brands, including RYTHM and Dogwalkers. Third, continuing to invest our resources and capital in markets where we can underwrite strong returns. The balance of our 2024 CapEx plan is to continue retail and wholesale investments in Florida, Nevada, Minnesota, Pennsylvania, and Virginia. It's no coincidence that four of these five markets have yet to establish an adult-use program. Last, preparing for our momentous second Miracle in Mundelein on September 7th and 8th at our flagship Illinois store in Mundelein. For those unfamiliar, this two-day festival for attendees 21 and over allows for legal cannabis consumption. This year's event showcases Raekwon, Slightly Stoopid, and Rebelution. We hope to see you there. In conclusion, we did want to call out hemp as we've received a lot of questions on this topic. As previously disclosed, we entered the hemp market via a license agreement with our Incredibles brand. Through that relationship, we are studying the consumer, the players, the product, the risks, and other facets of the market, including the overall potential. Since we are in the early days of our exploration, it'd be premature for us to comment more than that. However, our North Star always has been and always will be the consumer. With that, I'll turn the call over to Matt to review our financial results. Matt? Thanks, Anthony, and hello, everyone. We're pleased with the strong results and record cash flow generation. In the second quarter, we delivered over $280 million in revenue, an 11% increase compared to the prior year period. Revenue during the quarter benefited from 11 incremental retail stores and the legalization of adult-use sales in Maryland. While pricing year-over-year continued its downward slide, the sequential impact took a turn for the worse in Q2 compared to Q1's improvement. Overall, retail revenue increased 9% versus the prior year period. Second quarter comparable sales increased 2.3% compared to the second quarter last year on a base of 76 stores. Consumer packaged goods gross revenue increased 15% versus the prior year quarter. Looking forward, we expect to see third quarter sequential revenue to be flat as we watch macro consumer spending pull back with some expected benefit from Ohio adult-use launch. Gross profit for the second quarter was $151 million, or 53.7% of revenue, compared to $125 million, or 49.6% of revenue, for the second quarter last year. The increase in gross margin was primarily driven by improved CPG utilization and retail acquisition costs. Turning to OpEx, selling general administrative expenses for the second quarter were $97 million, or 34% of revenue, compared to $84 million, or 33% of revenue last year, with compensation costs driving the-... G&A excluding depreciation, amortization, one-time transaction costs, and stock-based income, which we refer to as normalized operating costs, approximated $67 million, compared to $57 million in the second quarter of last year. The increase year-over-year is mainly attributed to the 11 incremental retail stores. Second quarter net income was $21 million, or $0.09 per basic and diluted share during the quarter. This compares to net income of $13 million or $0.05 per basic and diluted share reported last year. Adjusted EBITDA, which excludes non-cash stock-based compensation and other non-operating costs, was $94 million or 33.5% of revenue for the quarter, as compared to $76 million, or 30% of revenue for the second quarter last year, with the increase driven by margin improvement. We ended the second quarter with a strong balance sheet, including cash of $196 million, and cash flow from operations of $104 million, compared to $93 million last year, all while paying $53 million in income taxes so far this year. In closing, I'm very proud of our team for all their hard work and execution in the second quarter. I'm confident in our ability to continue to execute our strategic plan, deliver high-quality cannabis to our patients and customers, all while generating strong returns for our shareholders. With that, we'll open the call to your questions. Operator? Thank you. We will now begin the question-and-answer session. To ask a question, you may press star, then one on your touch tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star, then two. In the interest of time, we ask that you please limit yourself to one question only. At this time, we will pause momentarily to assemble our roster. The first question comes from Matt Bottomley with Canaccord Genuity. Please go ahead. Yeah. Good evening, everyone. Thanks for the question. Ben, just wondering if I can get a little more color from you, with respect to your anticipation in Ohio, not in terms of specific, you know, monetary guidance or anything like that, but if you relate it to maybe what we saw in Maryland, where that was almost, you know, effectively a doubling of the market within months. Given that you're already at the state level max of five, I'm just wondering if you can give us an idea of what the back half of the year might suggest, considering that market's turning online tomorrow. Yeah. Hey, Matt. Thanks. Ben, yeah, you're right. I mean, just to level set for everybody, on Friday, we learned that Ohio would start adult-use tomorrow, so Tuesday of this week, which is tomorrow. For RISE, that means all five stores will convert to 21 and older, folks can come in and buy for the first time, and this is not new for us, right? Like you said, Matt, we, we led the charge in New Jersey, we led the charge in Maryland, we led the charge in Illinois. We've been around for Nevada, Massachusetts, New York, and several others. So, you know, we're optimistic. I'm not sure what else to tell you except numbers. So the numbers I would tell you are, yeah, we think it's easily a double as a market. You know, holistically, it should be bigger. You know, Ohio has been hampered for several different reasons: product, branding, sizing. You know, we're optimistic about the new regulator in the future, and we're excited about tomorrow. So, you know, we don't see a gangbuster boulder in a pond start. We see crawl, walk, run, making sure this thing gets off to a good start, and everybody's on the same page, and we're excited for tomorrow. I'll be out there. Everybody's welcome, 21 and over, bring your ID, and we'll see you at RISE throughout Ohio. Sorry, any capacity constraints in that market? Just to slip another quick one in there. Yeah, Matt, I can take that question. So, you know, we are fully built out. So for everyone's benefit, the store or the state has a, at least before adult-use started, had a statutory limit of five stores per operator and then had a canopy cap. So we were at the max on both of those limits. Now, with adult-use, the canopy cap increases, as well as the store count, it goes from five to eight. But at the moment, we're fully locked and loaded, and then obviously, when the adult-use rates go into effect in early September, that's when we'll take a closer look at the canopy expansion, along with, w e already have a path to open up the additional stores from five to eight. Okay. Thanks, all. Thanks, Matt. Again, in the interest of time, we ask that you please limit yourself to one question. The next question comes from Eric Deslauriers with Craig-Hallum Capital Group. Please go ahead. Great. Thanks for taking my questions, and, congrats on another impressive quarter here. So your ability to continue gaining market share and realizing operating efficiencies, continues to be impressive. Can you talk about where you see opportunities to continue that momentum and how that plays into your CapEx plans for the second half? And then just kind of higher level, should we be thinking about your efficiency gains and ability to kind of offset price compression as more a function of CapEx projects or operating cost leverage? Thank you. Yeah, I can start, Eric, and maybe Anthony will come in on the second part. So I, I think the first part is where, where's the growth, where are we optimistic going forward? And I think, you know, we think you have an edge on the vision of what's happening in cannabis in the country. So it's sort of like have the pieces in place ahead of time, which means tomorrow morning, open five stores for non-medical sales in Ohio. And what that means in, in the next year or two, are places like Virginia, Minnesota, and a few other states on the market, and then it's even thinking outside the box and being ahead of that. So, you know, and we have the balance sheet to do it, and we have the ability and the powder, you know, to make a few mistakes too, and not tip over the boat. So we see our ability to play offense and really accelerate on the gas, and press big time. You know, that's what we're doing for the advantage of shareholders. So it's a pretty good situation where we are there. In terms of the actual details of the operating efficiencies and price? Yeah, look, I think, just as we look ahead. You know, I think we're showing it in terms of kind of where we're allocating capital, right? And the fact that we continue to allocate capital. We've been one of the bigger kind of, you know, investors of into our business than any other operator. And as we look ahead, you know, we've had to continue to sharpen the pencil and just make sure that the returns continue to pencil out for the shareholders. And so, you know, now, I think in my prepared remarks, I mentioned that where we're allocating the dollars really is Florida, Nevada, Minnesota, Pennsylvania, and Virginia. Now, how that evolves over time, we'll see. But we see opportunities within those markets to deploy capital as returns that make sense for shareholders. You know, and then in terms of our performance and ability to continue to kind of, you know, drive strong operating performance, it's on the heels of the capital spend. So, you know, as we enter in these markets, we stand up the facilities, we continue to optimize kind of our presence within those facilities, and we grow into them, and that's how we've been able to continue to, you know, effectively show strong kind of, you know, margin performance. On top of that, you know, it's all supported by the strength of our brand and the quality of our products, and that's gonna continue to be kind of, you know, two pillars that we're gonna have to continue to lean on as these markets, you know, just continue to become more competitive and more challenging. It's all very helpful. Thank you for taking my question. The next question comes from Pablo Zuanic with Zuanic & Associates. Please go ahead. Thank you. Ben, can you maybe give more context regarding your letter to Jim Koch regarding the merger with Boston Beer Company? I mean, obviously, I know it's something that you guys have thought through very carefully, and it's not a publicity stunt, for sure. But, you know, they are low growth, right? Why dilute your story with a low-growth company? The idea of a U.S. listing, I mean, there's no, the, Boston Beer Company could lose their Nasdaq listing if they were to merge with a plant-touching company, right? At least that's what we've seen from other cases, even the ones that are trying to have ring-fence structure. So maybe just some context about what you tried to do there. And then number two, if I can, I know you said not a lot of comments on hemp. From my perspective, there are good players out there in hemp that are, you know, following the rules, and their products are tested, and they have, and they go through labs in the various states, and that's why probably you chose LFTD Partners as, as a partner there. But maybe give a bit more context, if you can, because I find that when I read out there, it sounds like everything that's hemp-derived is bad, and obviously, there are products that are properly produced and tested. Thank you. Sure, I can start. Yeah, thanks, Pablo. It's Ben. I mean, you know, I honestly don't have much more to say than the letter. I think we've been pretty forthcoming in what our thinking is, so I'm not gonna re-articulate it here. I think just for the record, there are listed companies on U.S. exchanges that own licenses to operate marijuana in regulated markets. They're taking in revenue, and they're listed. So we, you know, we think a U.S. listing is just a matter of time, the right lawyers, the right conversations, and the right sort of blow of the wind for people to feel the right cover. But again, for U.S. American citizens to not be able to buy stock in the American company that rolls the, the joints that they smoke doesn't make any sense. So eventually, we know that that's gonna be a fact. And, you know, buy what you own. Peter Lynch-style investing should take over for this sector because American consumers, especially young, new, interested consumers, wanna have access to this sector, and so far, it's been blocked out. Doesn't make sense. Again, there's 428,000 Americans that work in cannabis, and they're all breaking federal law right now. And, you know, everybody in D.C. seems distracted and not quite able to get around to it, so it's, it's quite frustrating. But we view Green Thumb as a listing on the U.S. exchange here eventually. I can't tell you when, but obviously, we would follow in the footsteps of the other big companies that are listed on the New York Stock Exchange or Nasdaq that are in the marijuana business. From the hemp? Yeah, and I think, I mean, yeah, Pablo, good, good call out and good comments on hemp. You know, again, I think my prepared remarks kind of said it best. We're at the very early stages of our exploration here. You know, and one of the things I said, we're studying the players. So absolutely, there are some operators that we've come across that seem to be doing a nice job. Unfortunately, not everyone seems to be kind of falling within that, those same guidelines. But we're at the early stages, and my guess is, over time, you know, we'll start to kind of really peel back the onion here and understand how and if we play in this market. You know, we also said that the consumer is really what our main focus on. So that, at the end of the day, we're gonna be focused on that, and so, you know, we have to keep our eyes wide open as this game continues to evolve. Thank you. The next question comes from Aaron Gray with Alliance Global Partners. Please go ahead. Hi, good evening, and thank you for the question. Nice question. Nice execution on the CPG side of the business, you know, both year-over-year, but also on a mid-single-digit basis, taking away the Maryland adult-use impact. So could you provide some color in terms of, you know, standouts in terms of formats or brands or where you have seen the most success in the first half of the year for that? And then, you know, you spoke about pricing pressure in this, in this sector. You know, can you speak to your current comfortability in terms of the price gaps within respective price segments and whether or not that's changed and driven some success that you've seen? Thank you. Standout formats. All right, Aaron, there's a lot of... You were, you were coming through, a little, little muddled there, but your first question related to specific to Maryland in terms of the products and the brands that are having a lot of traction in the market. Is that it? it? Did I catch that right? No, no. First question was just, overall CPG success and, and what formats or brands have been standouts? Okay. So yeah, let's answer that first. So in terms of the products and the brands, we look, it's, you know, RYTHM and Dogwalkers, along with strength within Incredibles and Beboe, depending on the market and where they're launched. Right, but overall, we're pretty pleased with, you know, and we look, we look at the same data as everyone else. We take a look at BDS and Headset data, and, you know, in many markets, we're making strong progress. There are some markets where maybe we're not making the progress that we'd like to be making, and I can tell you we're gonna be working hard on those. But taking a step back, we feel really good about the progress that we've made thus far. And again, it comes back to high-quality products, right? We've got strength within the flower category, given how we kind of built this business with, you know, highly automated indoor facilities that can achieve, you know, just exceptional kind of, you know, humidity and temperature levels and whatnot. So So we have the ability to produce the high-quality flower. That helps us on the RYTHM side as well as the Dogwalkers side of the business. And then it's really just continuing to meet the consumer with where the demand is, you know, within a category such as pre-roll that, you know, that has some nice growth associated with it. So that's really where we've been focused, and so far, we've had some nice success that is showed up in the numbers within the first half of the year. Okay, great. Thanks. Yeah, the second part of that was just, your comfortability in terms of price gaps within, respective price segments for your brands. Look, here, the data is much more murky, and the real challenging factor is like-for-like SKUs. And particularly right now, what we're seeing, you know, with the consumer, you know, just on the retail side, we're, you know, the store visits are there, the traffic is there, but there's an essential kind of just trading down in bulk purchasing that's happening, that effectively is driving down, you know, the overall, you know, revenue per gram, if that's the metric that you track, which for us it is. So it's hard to really look at apples to apples, compare it against kind of, you know, other brands, other categories, like for like. It's just incredibly challenging. So for us, you know, the way that we're looking at it is, you know, we look at how we're pricing our own products within our own retail stores relative to third-party products, and if we can get a sense for value, and we feel good about the value that, that effectively our products are carrying on the shelf, that's, that's really the first step, and that's what gives us the confidence that we're pricing our product correctly. Okay, great. Thanks for that. I'll jump back in the queue. The next question comes from Frederico Gomes with ATB Capital. Please go ahead. Hi, thanks for taking my question. Congrats on the quarter. Just on New York, could you just comment on what you're seeing there in the adult use market, especially, you know, with the crackdown that we're seeing, on the illicit store side. Are you seeing any meaningful benefits from that enforcement against the illicit market? And do you think that, you know, New York got to a point where, you could see that market thriving, finally? Thanks. Sure. Anthony here. I know everyone's heard from quite a bit already, but I'll take that one. So on New York, with zoom out, as of today, we have five stores in New York. We opened up our latest store in Syracuse late last week. And, you know, look, I'll tell you that the market overall has received kind of an injection of life ever since we started seeing the state crack down on these stores. And we're seeing it because we're feeling the demand on the wholesale side of the business pulling through, particularly at the retail stores that are within that, within kind of the city limits. And so we can already tell it's starting to have an impact. I mean, obviously, you know, we think they're at the early stages of this, and there's a lot more room to grow. But just given the size of state, we're finally starting to see life within a market with over 20 million people that we all kind of anticipated would be there, call it, you know, 5, 10 years ago. So, you know, the early stages seems like it's working, but there's more, you know, there's more work to do. We'll continue to monitor it, but, but, but definitely, it's having an impact. If anything, it's just, you know, the, the morale of the industry within New York is a lot more positive now that, you know, it seems like, you know, it's just one less, you know, one less kind of front we have to, we inevitably have to fight. Thank you. The next question comes from Mike Regan with Excelsior Equities. Please go ahead. Hi, everyone. Thanks for the question. I guess turning to sort of the, the spending in Florida, is that more just to build out the existing medical market if adult-use doesn't pass in November, or is it sort of an anticipation of adult-use passing in November? Sort of on that, I guess, any, any thoughts on, I guess the Yes on 3 campaign and additional contributions, especially now that Ken Griffin is donating $12 million to fight it? Thanks. Yeah. So, Anthony here. Mike, I'll, I'll take that one as well. You know, look, what we're investing into Florida irrespective of the vote in November, right? So the vote in November is just essentially more optionality on the business. You know, look, given the vertically integrated nature of that market, you have to invest essentially within wholesale before retail. We've done that. We're gonna continue to make additional wholesale investments, and we're gonna continue to make additional retail investments. Now, the investments we're making today is not a bet on adult-use. Now, if and when the vote goes our way, the industry's way in November, that will probably force us to revisit our capital plans in the state of Florida and revisit it then. In terms of how, you know, how the ballot initiative is looking at this moment, I mean, look, we're a number of months away. It's pretty premature at this point to really comment on it because, again, there's a lot of games being played. There's more dollars and donations that are gonna be coming in on both sides. And the reality is that, you know, ask in a couple of months, and we'll have a better sense for where this thing is really tracking. But here at Green Thumb, we're investing in the market irrespective of the vote in November. Got it. Great. Thanks a lot. The next question comes from Scott Fortune with Roth Capital Partners. Please go ahead. Good afternoon. Thanks for the questions. Just want to call out, we've talked a little bit about the consumer, but just want to provide a little more color on the overall consumer strength here. You guys called out, there's data indicating a tougher macro consumer spending. You guys called that out, but how is volume transactions holding up, and your thoughts of where that's coming from, from that side of the things on the consumer side? As pricing coming down, are we seeing more consumers kind of converting from the listed market or a substitution effect away from alcohol? Just kind of your overall sense on the consumer and how you guys are positioned to benefit from those trends as you see it going forward here. Hey, Scott. Yes, Ben, I can take that. You know, I would say overall, we see the impact. We don't think the consumer is as strong as they were, but we see demand in cannabis not letting up. So transactions are not, you know, tickets are not suffering in transaction volume. You know, how to define the demand pie in cannabis remains pretty interesting and remains expansive and morphing. What happens to the rules, and what's going on with the illegal market, and what's happened, and what's at the vape store, and all that sort of thing. So we continue to try to cater towards that consumer. We think the consumer is price sensitive. People care about how many dollars are in their pocket. You only have to look to, like, the major retailers of the country to see major signs of weakness and even today's market, et cetera, et cetera. So, we don't think cannabis is totally immune, but the demand is there. The demand remains strong. The demand remains strong even when things get bad. You know, we think we'll see that with the election, with other things coming up. So, you know, headline numbers, that the industry is annualizing at over $30 billion. That's the first time that's happened. This thing is strong and getting stronger. So that's why I said we're confident in the future of cannabis for the American consumer. We're very confident in Green Thumb. We've got the buyback going. We're bullish on what we're doing here. It's a very complicated environment, and just as we conclude here, what's going on in the regulatory environment is pretty unique. We've been running the business for 10 years, and, you know, we've never quite seen anything like this, and nobody really knows what's going on. Nobody knows what's going on macroly, but nobody really knows what's going on in cannabis. So we're focused on how great the product is. We believe in our brands, we believe in the future. So, you know, we hope those of you that are analyzing the industry that aren't yet invested, take a real look. There's a unique opportunity. We're coming to work excited every day and, and, you know, look forward to talking to you again in 90 days. Thanks, Scott. Thanks, everybody. This concludes our question and answer session. I would like to turn the conference back over to Ben Kovler for any closing remarks. That'll do it. Talk to you guys in 90 days. The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.